Print view
 

Studies Yield ‘Impressive’ Results in Fight Against Cystic Fibrosis

“These findings indicate that it may soon be possible to offer safe and effective molecularly targeted therapies to 90 percent of persons with cystic fibrosis,” wrote the director, Dr. Francis S. Collins, who led the team that in 1989 identified the gene that causes the genetic disease affecting the lungs and digestive system. “This should be a cause for major celebration,” he wrote in the Thursday editorial.

The two studies, published by The New England Journal of Medicine and The Lancet, describe the results of clinical trials of a three-drug therapy for people with cystic fibrosis, which causes thick mucus to build up in the lungs and other parts of the body and drastically shortens life expectancy. Both studies found that, among other things, patients who received the therapy showed improvement in a key measure of lung capacity, findings that Dr. Collins described in a separate N.I.H. blog post as “striking. Xannonce

The studies were conducted with funding from Vertex Pharmaceuticals, which developed the triple-combination drug therapy, known as Trikafta. Last week, the Food and Drug Administration approved Trikafta for use with about 90 percent of patients with cystic fibrosis — those who have the most common cystic fibrosis gene mutation and are 12 or older.

Read the full aricle here.

Autor: Niraj Chokshi   Quelle: The New York Times, 04.11.2019
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
Weitere News
COVID-19 severity affected by proportion of antibodies targeting crucial viral protein
2020 New York Times Voices
COVID-19 Dashboard EN/PT
WHO Coronavirus Disease (COVID-19) Dashboard
ECDC and WHO call for improved HIV testing in Europe
GHD|EMPHNET Launches Online Courses on Response to Public Emergencies
EUPHA strategy 2020-2025
150 years of the International Review of the Red Cross
Fast coronavirus tests: what they can and can’t do
Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe
Introducing and lifting non-pharmaceutical interventions (NPIs) on SARS-CoV-2 reproduction number (R) across 131 countries.
Take Action to Prevent the Flu
Three Ways Forward in a Post Covid-19 World
Gender-sensitive Workplace Health Promotion: Why It Is Important and How It Can Be Implemented in Practice
COVID-19: the worst may be yet to come
Medicine shortages in the EU: causes and solutions
Coronavirus Makes Inequality a Public Health Issue
A ‘Cure’ for Ebola but Will it Stop the Outbreak if People Won’t Get Treatment?
The Role of Women’s Organisations in Crisis-Settings
CRA shortage is worsening while demand grows – a vicious circle which opens masses of job opportunities
Why Doctors Hate Their Computers
Junior hospital doctors
90–90–90 Treatment for All
Incident Management System
Incident Management System
An Economy for the 99%
European Virus Archive goes global
Establishing a Global Vaccine-Development Fund

educational newsletter

 

Österreichische Akademie der ÄrzteHelix - Forschung & Beratung WienSwiss Tropical and Public Health InstituteAlumni Club Medizinische Universität WienÖsterreichisches Rotes KreuzCharité International AcademyEuropean Health Forum GasteinnewTree